May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Activated Protein C Inhibits Tissue Plasminogen Activator-Induced Retinal Toxicity
Author Affiliations & Notes
  • Z.-J. Du
    Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan
  • M. Kamei
    Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan
  • M. Suzuki
    Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan
  • K. Nishida
    Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan
  • H. Sakaguchi
    Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan
  • P. Xie
    Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan
  • Y. Tano
    Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan
  • Footnotes
    Commercial Relationships  Z. Du, None; M. Kamei, None; M. Suzuki, None; K. Nishida, None; H. Sakaguchi, None; P. Xie, None; Y. Tano, None.
  • Footnotes
    Support  Grant-in-aid for Scientific Research (#15591853) from the Ministry of Education, Science and Culture of Japan
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4885. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Z.-J. Du, M. Kamei, M. Suzuki, K. Nishida, H. Sakaguchi, P. Xie, Y. Tano; Activated Protein C Inhibits Tissue Plasminogen Activator-Induced Retinal Toxicity. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4885.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Tissue plasminogen activator (tPA) has been applied for several ocular disorders, although excessive doses of intravitreal tPA cause retinal toxicity. Previous works demonstrated that tPA toxicity to brain tissues increases under ischemic conditions and that activated protein C (APC) inhibits tPA toxicity. The purpose of this study was to analyze tPA toxicity in the ischemic retina and to evaluate the protective effect of APC against tPA toxicity in the retina.

Methods: : Retinal pigment epithelium cells (ARPE-19) were cultured, and placed either under a normoxic condition or in a hypoxic chamber to induce an ischemic condition. The cultures were then treated with 2.5, 5, 10, 20, or 40 µg/ml of tPA for 24 hours, followed by MTT assay and TUNEL staining to determine the number of viable cells and apoptotic cells, respectively. Activity of caspase 3, 8, and 9 was also analyzed. To examine the potential inhibitory effect of APC against tPA-induced cyototoxicity, the cultures were treated with APC (ranging from 3 to 240 µg/ml) alone or with a mixture of tPA with APC. To detect the in vivo effects of tPA and APC, various concentrations of tPA, APC, and the mixture were intravitreally injected in a rat central retinal vein occlusion (CRVO) model, followed by TUNEL staining 24 hours after the injection.

Results: : The number of dead cells increased in a dose-dependent manner under a normoxic condition when treated with 20 µg or greater tPA and significantly increased under a hypoxic condition (P=0.002). Lower concentrations of APC (ranging from 3 to 60 µg/ml) showed a cell protective effect against hypoxia, while higher concentrations of APC (120 µg/ml or greater) demonstrated cytotoxicity. TPA-induced cytotoxicity was significantly suppressed by 6 µg/ml of APC both in vitro and in vivo. Caspase 3, 8, and 9 were activated when cells were subjected to hypoxia or treated with tPA, and this activation was significantly inhibited by APC (P<0.001).

Conclusions: : APC can reduce the cytotoxicity induced by tPA both in vitro and in vivo via blocking the activation of caspase 3, 8, and 9. APC might be a promising candidate not only to suppress tPA cytotoxicity but also to protect the retina from ischemic conditions.

Keywords: retina • ischemia • apoptosis/cell death 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×